Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 59, 4776-4780, October 1, 1999]
© 1999 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Macdonald, N.
Right arrow Articles by Roberts, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macdonald, N.
Right arrow Articles by Roberts, R. A.
[Cancer Research 59, 4776-4780, October 1, 1999]
© 1999 American Association for Cancer Research


Advances in Brief

Addition of Peroxisome Proliferator-activated Receptor {alpha} to Guinea Pig Hepatocytes Confers Increased Responsiveness to Peroxisome Proliferators

Neil Macdonald, Peter R. Holden and Ruth A. Roberts1

AstraZeneca Central Toxicology Laboratory, Alderley Park, Macclesfield SK10 4TJ, United Kingdom

The fibrate drugs, such as nafenopin and fenofibrate, show efficacy in hyperlipidemias but cause peroxisome proliferation and liver tumors in rats and mice via nongenotoxic mechanisms. However, humans and guinea pigs appear refractory to these adverse effects. The peroxisome proliferator (PP)-activated receptor {alpha} (PPAR{alpha}) mediates the effects of PPs by heterodimerizing with the retinoid X receptor (RXR) to bind to DNA at PP response elements (PPREs) upstream of PP-regulated genes, such as acyl-CoA oxidase. Hepatic expression of PPAR{alpha} in guinea pigs and humans is low, suggesting that species differences in response to PPs may be due at least in part to quantity of PPAR{alpha}. To test this hypothesis, we introduced mouse PPAR{alpha} and its heterodimerization partner, RXR{alpha}, into guinea pig hepatocytes by transient transfection and determined responsiveness to the PP nafenopin by cyanide-insensitive palmitoyl-CoA oxidation (CIPCO). Expression of the mRNA for mouse PPAR{alpha} in transfected guinea pig hepatocytes was verified using species-specific PCR. In guinea pig hepatocytes transfected with control plasmids and treated with 50 µM nafenopin in the absence or presence of the RXR ligand, 9-cis-retinoic acid (5 µM) gave only a 1.7 ± 1.5- or 3.3 ± 1.5-fold induction in CIPCO, respectively. However, addition of ligands to hepatocytes co-transfected with both mPPAR{alpha} and RXR gave a strong induction of CIPCO (14.8 ± 8.6-fold). Mouse, human, and guinea pig PPAR{alpha} showed equivalent function in the CIPCO assays. Thus, quantity of PPAR{alpha} plays a significant role in the lack of response to PPs in guinea pigs. In humans, however, lack of PPAR{alpha} may be only one factor dictating lack of response because recent data show that the human acyl-CoA oxidase gene lacks a functional PP response element.




This article has been cited by other articles:


Home page
Toxicol SciHome page
Q. Yang, T. Nagano, Y. Shah, C. Cheung, S. Ito, and F. J. Gonzalez
The PPAR{alpha}-Humanized Mouse: A Model to Investigate Species Differences in Liver Toxicity Mediated by PPAR{alpha}
Toxicol. Sci., January 1, 2008; 101(1): 132 - 139.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
L. Canaple, J. Rambaud, O. Dkhissi-Benyahya, B. Rayet, N. S. Tan, L. Michalik, F. Delaunay, W. Wahli, and V. Laudet
Reciprocal Regulation of Brain and Muscle Arnt-Like Protein 1 and Peroxisome Proliferator-Activated Receptor {alpha} Defines a Novel Positive Feedback Loop in the Rodent Liver Circadian Clock
Mol. Endocrinol., August 1, 2006; 20(8): 1715 - 1727.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
M. Ammerschlaeger, J. Beigel, K.-U. Klein, and S. O. Mueller
Characterization of the Species-Specificity of Peroxisome Proliferators in Rat and Human Hepatocytes
Toxicol. Sci., April 1, 2004; 78(2): 229 - 240.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M.-H. Hsu, U. Savas, K. J. Griffin, and E. F. Johnson
Identification of Peroxisome Proliferator-responsive Human Genes by Elevated Expression of the Peroxisome Proliferator-activated Receptor alpha in HepG2 Cells
J. Biol. Chem., July 20, 2001; 276(30): 27950 - 27958.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. W. Lawrence, Y. Li, S. Chen, J. G. DeLuca, J. P. Berger, D. R. Umbenhauer, D. E. Moller, and G. Zhou
Differential Gene Regulation in Human Versus Rodent Hepatocytes by Peroxisome Proliferator-activated Receptor (PPAR) alpha . PPARalpha FAILS TO INDUCE PEROXISOME PROLIFERATION-ASSOCIATED GENES IN HUMAN CELLS INDEPENDENTLY OF THE LEVEL OF RECEPTOR EXPRESSION
J. Biol. Chem., August 17, 2001; 276(34): 31521 - 31527.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.